Evidence map›Paper›PMID 42797866›Full record

ReviewViruses2026

Modulation of DNA Damage by Epstein-Barr Virus (EBV).

Emily DiMaulo-Milk, Blossom Damania

Abstract readReview
In one paragraph

Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emily DiMaulo-MilkLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Blossom DamaniaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-9205-1774

Funding

CANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0M
Therapy for Non-Hodgkin lympomaR01CA291437 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLOSSOM A DAMANIA · 2024 to 2026
$2.2M
Targeting EBV-associated lymphomasU01CA294800 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLOSSOM A DAMANIA · 2024 to 2026
$1.9M
NCI NIH HHS R01 CA291437NCI NIH HHS T32 CA071341NCI NIH HHS U01 CA294800NIH HHS
6 · The paper itself

Abstract

Epstein-Barr Virus (EBV) is an oncogenic gammaherpesvirus present in >95% of the adult population. EBV is responsible for nearly 2% of the global cancer burden and is a contributing factor in the development and progression of both epithelial and lymphoid malignancies. Throughout its lifecycle, EBV manipulates the DNA Damage Response (DDR). Aberrations in the DDR pathway result in genomic instability, a hallmark of cancer. In this review, we explore how EBV gene products expressed during lytic reactivation and latency promote genomic instability by creating a genotoxic environment and interacting with components of the DDR. Additionally, we describe viral genes capable of suppressing critical checkpoints which facilitate repair of damaged DNA. The ultimate failsafe in the case of catastrophic DNA damage is senescence or cell death, processes which are suppressed by EBV gene products. We also discuss how EBV appropriates DDR machinery to replicate its own genome during lytic reactivation. The manipulation of DDR proteins is essential for EBV-induced immortalization of primary B-cells infected in vivo, and viral strains engineered to lack these genes show reduced or ablated transformation efficacy, demonstrating the critical role of the DDR in EBV-induced oncogenesis.

Indexed as

DNA DamageEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHost-Pathogen InteractionsAnimalsB-LymphocytesDNA RepairGenomic InstabilityHumansViral ProteinsVirus ActivationVirus LatencyViral ProteinsBurkitt lymphomaBZLF1DNA damage response (DDR)EBNA1EBNA2Epstein–Barr virus (EBV)herpesvirusesLMP1oncogenic virusesreactive oxygen species (ROS)

Identifiers

PMID42797866
PMCPMC13612100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.